The marriage of artificial intelligence and pharmaceutical advertising has never been what one might call a love match. Regulators worry about hallucinations — the AI kind, though the other sort is not entirely irrelevant when discussing drug marketing — and advertisers worry about brand safety in an environment they cannot fully control.
Yet Google, which has spent the better part of two decades refining the delicate choreography of prescription drug advertising on its search platform, has decided the time has come to let pharmaceutical marketers into its newer AI-powered features.
The company confirmed this month that it has begun testing standard text and Shopping ads for pharmaceutical products, including prescription drugs, within AI Mode and AI Overviews. The test is limited to the United States, where the rules governing direct-to-consumer drug advertising are, to put it gently, more permissive than elsewhere in the world. (Only the United States and New Zealand allow such advertising on television, a fact that explains much about the commercial breaks during evening newscasts.)
The ads will appear in sections labeled "Sponsored," according to a Google spokesperson, which suggests the company is taking pains to maintain the church-and-state separation that has governed search advertising since the medium's infancy.
For pharmaceutical marketers, the move represents an opportunity to appear in the conversational interfaces that are increasingly replacing the traditional blue links of search results pages. For Google, it represents a way to monetize AI Mode, which has been notably light on advertising inventory since its introduction.
Whether users seeking AI-generated health information will welcome the arrival of prescription drug ads in their results is, as they say in the pharmaceutical business, a matter requiring further study.
Original story published in adweek.com: "Google Opens AI Mode to Prescription Drug Ads"